Jason Rushton
Director/Board Member at Aria CV, Inc.
Profile
Jason Rushton is currently a Director at Aria CV, Inc., Oncomyx Therapeutics, Inc., and a Partner at Xeraya Capital Sdn.
Bhd.
He was formerly an Independent Director at Liquidia Technologies, Inc. Rushton received both his undergraduate and graduate degrees from the University of Birmingham.
Jason Rushton active positions
Companies | Position | Start |
---|---|---|
Xeraya Capital Sdn. Bhd.
Xeraya Capital Sdn. Bhd. Investment ManagersFinance Xeraya Capital Sdn. Bhd. (Xeraya Capital) is a venture capital firm founded in 2006 by Amirul Fares Wan Zahir. The firm is headquartered in Kuala Lumpur, Malaysia. | Private Equity Investor | - |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | Director/Board Member | - |
Aria CV, Inc.
Aria CV, Inc. Medical SpecialtiesHealth Technology Aria CV, Inc. develops medical devices. It designed to improve the lives of patients living with the disease of pulmonary hypertension. The company was founded by John Scandurra and Karl Vollmers in 20101 and is headquartered in St. Paul, MN. | Director/Board Member | - |
Former positions of Jason Rushton
Companies | Position | End |
---|---|---|
Liquidia Technologies, Inc.
Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Director/Board Member | - |
Training of Jason Rushton
University of Birmingham | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 4 |
---|---|
Liquidia Technologies, Inc.
Liquidia Technologies, Inc. Pharmaceuticals: MajorHealth Technology Liquidia Technologies, Inc. is a clinical biopharmaceutical company focused on the development and commercialization of human therapeutics using its proprietary PRINT technology to transform the lives of patients. It operates in two segments: Pharmaceutical Products and Partnering & Licensing. The two product candidates from its pipeline: LIQ861 for the treatment of pulmonary arterial hypertension and LIQ865 for the treatment of local post-operative pain. Liquidia Technologies was founded by Joseph M. DeSimone, Ashok K. Mendiratta, Edward T. Samulski, William R. Kenan, Ginger Denison and Jason Rolland in 2004 and is headquartered in Morrisville, NC. | Health Technology |
Aria CV, Inc.
Aria CV, Inc. Medical SpecialtiesHealth Technology Aria CV, Inc. develops medical devices. It designed to improve the lives of patients living with the disease of pulmonary hypertension. The company was founded by John Scandurra and Karl Vollmers in 20101 and is headquartered in St. Paul, MN. | Health Technology |
Xeraya Capital Sdn. Bhd.
Xeraya Capital Sdn. Bhd. Investment ManagersFinance Xeraya Capital Sdn. Bhd. (Xeraya Capital) is a venture capital firm founded in 2006 by Amirul Fares Wan Zahir. The firm is headquartered in Kuala Lumpur, Malaysia. | Finance |
Oncomyx Therapeutics, Inc.
Oncomyx Therapeutics, Inc. Packaged SoftwareTechnology Services Oncomyx Therapeutics, Inc. develops and operates software platform to orchestrate an immune response and treat cancer. Its platform's features include non-human pathogen, immuno-stimulatory, ability to multi-arm, and systemic delivery. The company was founded by Steve Potts, Michael Wood, Grant McFadden and is headquartered in Phoenix, AZ. | Technology Services |
- Stock Market
- Insiders
- Jason Rushton